Clearmind Medicine Inc. (NASDAQ:CMND) Stock Short Interest Report for October

Clearmind Medicine Inc. (NASDAQ:CMND) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 3,861 shares, a drop of 73.9% from the September 30th total of 14,819 shares. Based on an average trading volume of 35,857 shares, the short-interest ratio is presently 0.1 days. Currently, 0.8% of the shares of the company are short sold.

Clearmind Medicine Price Performance

Shares of CMND traded down $0.13 during mid-day trading on Thursday, reaching $5.93. The stock had a trading volume of 4,351 shares, compared to its average volume of 111,210. The firm has a market cap of $3.01 million, a price-to-earnings ratio of -0.02 and a beta of 0.93. Clearmind Medicine has a 12 month low of $5.25 and a 12 month high of $3,108.80. The business has a fifty day moving average of $8.42 and a 200 day moving average of $51.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 4.31.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings data on Thursday, September 10th. The company reported ($4.56) earnings per share (EPS) for the quarter.

About Clearmind Medicine

Clearmind Medicine Inc (NASDAQ: CMND) is a clinical-stage biotechnology company focused on discovering and developing psychedelic-derived therapeutics for underserved health conditions. The company’s research combines medicinal chemistry with the study of psychoactive compounds to identify treatments designed to address substance-use disorders and other metabolic or behavioral conditions.

Clearmind’s lead investigational compound is MEAI, also known as 5-methoxy-2-aminoindane. The company has evaluated MEAI in preclinical and early clinical research for potential applications including alcohol use disorder and binge drinking.